Beckman Coulter Genomics and Vitrology Ltd. Partner to Offer Comprehensive Biologics Testing Solutions
Alliance Provides One-Stop Biosafety Testing Service
DANVERS, Mass., and GLASGOW, UK (January 17, 2011) — Beckman Coulter Genomics and Vitrology Ltd. today announced a strategic partnership to offer customers a wide range of biosafety testing services. The alliance provides the biopharmaceutical industry with two inclusive sources for the full complement of molecular, in vitro and in vivo genomic services necessary for the identification, stabilization and purification of biological products.
The alliance also provides customers with access to the next generation sequencing technologies that are revolutionizing biology. It is widely recognized that massively parallel sequencing technologies hold incredible promise for the study of DNA sequence variation in vaccines, cell banks and gene therapy products, and allow the use of an open-question approach for the safety characterization of biologics.
“Partnering with leading-edge innovators to respond to the dynamic research needs of our customers worldwide is fundamental to our goals as a quality genomic services provider,” said Elena Jouravleva, global product manager for Biologics Testing Services at Beckman Coulter Genomics. “This alliance supplements Beckman Coulter’s existing biologics testing services, which have a focus on identity and stability testing, with Vitrology’s expertise in biosafety testing, in both Good Manufacturing Practice and Good Laboratory Practice environments.”
“We are pleased to partner with Beckman Coulter Genomics to offer the global biotechnology industry an array of scientific assays to fully characterize a wide range of biologics,” said Margaret Temple, CEO of Vitrology. “This dynamic new alliance is a natural fit, coupling Beckman Coulter Genomics’ sequencing and marketing capabilities with the experience of the Vitrology team to offer an expert source of safety testing with sequencing data and analysis. Both companies are committed to ensuring that they offer the appropriate range of assays to ensure clients can achieve regulatory authority approval for product safety.”
Beckman Coulter Genomics provides Sanger and next generation DNA sequencing, gene expression profiling, genotyping and biologics testing services. The collaboration between Beckman Coulter Genomics and Vitrology further expands and complements both companies’ extensive biologics testing services portfolios, which are available to clients worldwide.
About Beckman Coulter Genomics
Beckman Coulter Genomics, with headquarters in Danvers, Massachusetts, is a leading global provider of genomic services and nucleic acid purification products, serving life-science researchers and the pharmaceutical industry throughout the world. The company was created by combining Beckman Coulter’s Agencourt Bioscience with Cogenics. By providing technical expertise, combined with personalized service, Beckman Coulter Genomics delivers the highest quality data, robust analyses and innovative thinking. For more information, visit www.beckmangenomics.com.
About Beckman Coulter, Inc.
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than a quarter of a million Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represent about 80 percent of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com or www.beckmancoulter.com/75years.
About Vitrology Limited
Vitrology Limited is a contract testing organization based in Glasgow, Scotland, providing GMP and GLP assays to detect potential contaminants in biological products, as well as offering regulatory and consulting services. The company has a highly experienced team, whose members have tested a wide range of biopharmaceutical, vaccine and veterinary products, from pre-clinical to commercial stage, over a fifteen-year period. For more information, visit www.vitrologybiotech.com.
Please send READER INQUIRIES from this news release directly to Beckman Coulter, c/o
K. Delgado, Harte Hanks, 1753 South Pointe Avenue, Ontario, CA 91761. Or e-mail to k_delgado@harte-hanks.com.
Contacts:
Steve Ernst, Veris Communications
Phone: 973-702-7249
E-mail: veriscomm@gmail.com
Aaron Tull, Beckman Coulter Genomics
Phone: 919-379-5493
E-mail: atull@beckman.com
Margaret Temple, Vitrology Ltd.
Phone: +44 141 952 0022
E-mail: margaret.temple@vitrologybiotech.com
